tadalafil + tamsulosin

CKD-397 is an oral fixed-dose combination developed by Chong Kun Dang for benign prostatic hyperplasia. Public trial records identify it as a tadalafil and tamsulosin combination; pharmacokinetic studies evaluated tadalafil 5 mg with tamsulosin 0.2 mg, and a randomized Phase III study evaluated CKD-397 in patients with benign prostatic hyperplasia. Tadalafil selectively inhibits phosphodiesterase type 5, increasing cyclic guanosine monophosphate signaling and promoting smooth-muscle relaxation, while tamsulosin antagonizes prostatic alpha-1 adrenergic receptors to reduce smooth-muscle tone in the prostate and bladder outlet. ([patlynk.com](https://www.patlynk.com/trial/NCT02645890))

Other names

tadalafil + tamsulosin fixed-dose combination